Skip to main content
OpenTrials
Completed

NCT Number: NCT02668068

A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells

Pneumoconiosis is a kind of lung disease due to inhalation of dust such as silica(common named Silicosis), coal and rock dust, characterized by inflammation, coughing, and fibrosis. Currently there is no effective drug treatment. The whole-lung lavage(WLL) can effectively clear the protein-like substances and inhaled dust deposited in the alveoli and bronchioles, as well as the pulmonary alveolar macrophage(PAM) and the resulting induced inflammation, fibrosis induced factor, serve to improve respiratory function, relieve symptoms of efficacy, but can't slow down or reverse the progression of pulmonary fibrosis.

By taking large volume whole-lung lavage (WLL) as a conventional therapy, this study intends to observe and evaluate the safety and efficiency of combined large volume WLL with mesenchymal stem cell (MSC) transplantation for treatment of Pneumoconiosis. Moreover, the immune regulation effect between large volume WLL and combined large volume WLL with MSC transplantation will also be preliminarily investigated and discussed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumoconiosis Lung Diseases Lung Diseases, Interstitial Lung Injury Occupational Diseases Respiratory Tract Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

First Affiliated Hospital of the Third Military University, PLA (Southwest Hospital), Chongqing, Chongqing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18-70 years old.
  • Subjects had exposed to dusts with a long history.
  • Subjects with a clear clinical diagnosis to be silicotics or coal miners' pneumoconiosis patients.
  • Subjects with each detected index of pulmonary function test including FVC, FEV1 or MVV had exceeded 70% of the predicated value.
  • Subjects signed informed consent.

Exclusion criteria

  • Women of childbearing age at the stage of pregnancy or lactation, or those without taking effective contraceptive measures.
  • Subjects with syphilis or HIV positive antibody.
  • Subjects with infection aggravated within the past month.
  • Subjects suffering from any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, severe pneumonia, acute exacerbation of chronic bronchitis, AECOPD, severe and / or extremely severe COPD, etc..
  • Subjects suffering from other serious diseases, such as myocardial infarction, unstable angina, cirrhosis, and acute glomerulonephritis.
  • Subjects suffering from other life-threatening diseases with an estimated life-span less than 2 years.
  • Subjects with leukopenia (WBC less than 4x109 / L) or agranulocytosis (WBC less than 1.5x109 / L or neutrophils less than 0.5x109 / L) caused by any reason.
  • Subjects with severe renal impairment, serum creatinine> 1.5 times the upper limit of normal.
  • Subjects with liver disease or liver damage: ALT, AST, total bilirubin> 2 times the upper limit of normal
  • Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders.
  • Subjects with severe arrhythmias (such as ventricular tachycardia, frequent superventricular tachycardia, atrial fibrillation, and atrial flutter, etc.) or cardiac degree II or above conduction abnormalities displayed via 12-lead ECG.
  • Subjects with a history of alcohol or illicit drug abuse.
  • Subjects accepted by any other clinical trials within 3 months before the enrollment.
  • Subjects with poor compliance, difficult to complete the study.
  • Any other conditions that might increase the risk of subjects or interfere with the clinical trial.
  • Subjects accepted large volume whole-lung lavage treatment previously.

Treatment and study plan

large volume whole-lung lavage (WLL)

Procedure

Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification

clinical grade umbilical cord mesenchymal stem cells

Biological

10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)

    Time frame: 6 months

    Clinical adverse events evaluated as definitely/ probably/possibly concerned with large volume lung lavage and / or mesenchymal stem cell therapy in this trial, and abnormal results of laboratory tests or other special examinations will be observed and recorded in detail.

  2. Imaging indicator: Quantitative analysis of CT density histograms

    Time frame: 6 months after surgery

Secondary outcomes

  1. Clinical Indicator 1: change in blood gas analysis

    Time frame: 6 months

    Including PH, PaCO2,PaO2, HCO3

  2. Clinical Indicator 2: change in MRC chronic dyspnea scale

    Time frame: 6 months

  3. Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale

    Time frame: 6 months

  4. Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)

    Time frame: 6 months

  5. Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)

    Time frame: 6 months

  6. Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF

    Time frame: 6 months

  7. Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF

    Time frame: 6 months

  8. Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9

    Time frame: 6 months

  9. Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9

    Time frame: 6 months

  10. self-evaluation

    Time frame: 6 months

    Self-evaluation will be also classified into four levels: effective, improved, stable and invalid

Sponsors and collaborators

Lead sponsor

Jianwu Dai

Other Gov

Collaborators

  • Nanjing Chest Hospital
  • Southwest Hospital, China

Registry information

Official study title

A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jan 29, 2016
Registry last updated
Jul 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.